Kindai Faculty

Nov 11, 2024 | link.springer.com | Kindai Faculty

AbstractDespite the introduction of new drugs, multiple myeloma (MM) still remains incurable. We previously reported that CD34+ MM cells, which are clonogenic and self-renewing, are therapy-resistant and persist as a major component of minimal residual disease, expanding during relapse.

Nov 7, 2024 | giejournal.org | Kindai Faculty |Masayuki Kitano

1Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan 2Endoscopy Center, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan 3Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo, Japan 4Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan 5Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan 6Division of Endoscopy,...

Oct 5, 2023 | jamanetwork.com | Shukui Qin |Masatoshi Kudo |Kindai Faculty |Tim Meyer

Key PointsQuestion  How does the efficacy and safety profile of tislelizumab compare with that of sorafenib as first-line treatment among patients with unresectable hepatocellular carcinoma (HCC)? Findings  In this phase 3 randomized clinical trial of 674 patients with HCC, tislelizumab demonstrated overall survival noninferiority compared with sorafenib, with numerically higher and more durable objective responses than sorafenib.